TG Therapeutics Inc

TGTX remains in a Stage 2 advancing regime with clear higher-highs and rising EMAs, but a recent Bullish Exhaustion candle, extreme overbought readings, and extended price above the EMAs caution against immediate entry. We prefer to wait for a pullback into the rising 9EMA/21EMA zone near the prior breakout support for a tactical long. Key risk is a break and close below the 9EMA/21EMA, which would signal deeper correction.

• ↑Q1 2026 U.S. net product revenue $195M (+63% YoY) beat $185–190M guide.
• ↑Over 25,000 patients prescribed BRIUMVI, expanding real-world installed base.
• ↓Q1 EPS fell 40% short of estimates, highlighting profit risks.